Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutions's dividends per share for the
three
months ended in Mar. 2026 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.00. As of today, Emergent BioSolutions's Dividend Yield % is 0.00%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Emergent BioSolutions (STU:ER4) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Emergent BioSolutions's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Dividends per Share Related Terms
Emergent BioSolutions Dividends per Share Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs ELTP, NIKA, EOLS: Dividends per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Dividend Yield % falls into.
Emergent BioSolutions (STU:ER4) has a Dividends per Share of €0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Dividends per Share too high?
Emergent BioSolutions' current Dividends per Share is €0.00. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Dividends per Share compare to ELTP and NIKA?
Emergent BioSolutions' Dividends per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.18, compared to a current price of €6.57 — trading 57.1% above its estimated fair value. The current Dividends per Share is €0.00. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Dividends per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.57 is trading 57.1% above its estimated GF Value™ of €4.18.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
Dividends per Share: €0.00
GF Value™: €4.18 vs. price of €6.57 (57.1% above fair value)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for STU:ER4
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
